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Abstract
Ineffective delivery to intracellular sites of action is one of the key limitations to the use of 
antisense and siRNA oligonucleotides as therapeutic agents. Here, we describe molecular scale 
antisense oligonucleotide conjugates that bind selectively to a cell surface receptor, are 
internalized, and then partially escape from nonproductive endosomal locations to reach their sites 
of action in the nucleus. Peptides that include bombesin sequences for receptor targeting and a run 
of histidine residues for endosomal disruption were covalently linked to a splice switching 
antisense oligonucleotide. The conjugates were tested for their ability to correct splicing and up-
regulate expression of a luciferase reporter in prostate cancer cells that express the bombesin 
receptor. We found that trivalent conjugates that included both the targeting sequence and several 
histidine residues were substantially more effective than conjugates containing only the bombesin 
or histidine moieties. This demonstrates the potential of creating molecular scale oligonucleotide 
conjugates with both targeting and endosome escape capabilities.
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There are multiple approaches for employing oligonucleotides to influence the extent and 
pattern of gene expression. This includes using conventional antisense or siRNA molecules 
to selectively degrade mRNA,1,2 antagomirs to block the actions of miRNAs,3 splice 
switching oligonucleotides (SSOs) to alter gene expression patterns,4 decoys to block 
transcription factors,5 CpG rich oligonucleotides to stimulate the immune system,6 and 
triplex oligonucleotides for targeted mutagenesis.7 However, despite much research and the 
advent of multiple clinical trials,8,9 the development of oligonucleotides as pharmacological 
agents has been impeded by the fact that delivery of these large, highly polar molecules to 
their sites of action in the cytosol or nucleus is a very challenging problem.10,11
There have been two broad approaches to the delivery of oligonucleotides. One has been to 
incorporate oligonucleotides into various nanocarriers including lipoplexes formed using 
cationic lipids12,13 and polyplexes made with cationic polymers14,15 or with cationic cell 
penetrating peptides.16,17 Another approach has been to create molecular-scale conjugates 
where oligonucleotides are covalently linked to ligands that can bind with high affinity to 
specific cell surface receptors and thus promote entry via endocytotic pathways. This 
includes aptamer–siRNA chimeras that interact with the PMSA receptor in prostate cancer 
cells,18 a conjugate of siRNA with a CpG oligonucleotide to promote uptake via Toll-like 
Receptor 9,19 our own previous work using SSOs or siRNAs conjugated to peptide ligands 
for integrins20,21 or for G Protein Coupled Receptors (GPCRs),22 as well as other studies 
using peptide23 or carbohydrate ligands.24
A major difference between the two approaches is the utilization of membrane-disrupting 
strategies. Thus, cationic lipoplexes can enhance oligonucleotide delivery to the cytosol and 
nucleus by creating transient nonbilayer perturbations of cellular membranes.25 Some 
cationic polymers can cause endosome destabilization through the ‘proton sponge effect’.26 
By contrast, none of the receptor-targeted oligonucleotide conjugates discussed above had 
membrane-disrupting functions intentionally incorporated in their design. In the current 
study, we sought to evaluate the merits of including both a targeting ligand and an 
endosome-destabilizing moiety into molecular scale oligonucleotide conjugates. For 
targeting we chose a bombesin-like peptide sequence (BBN) that binds with high affinity to 
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BB2, a GPCR that is highly expressed in various carcinoma cells.22 For endomembrane 
disruption we chose to use multiple histidine moieties that are titratable at the pH range 
found in endosomes. There has been previous work using histidine-rich peptides to promote 
the delivery of plasmid DNA and of oligonucleotides.26,27 However, this has largely been 
via the formation of nanoparticle complexes between the peptides and the nucleic acid. Here 
we demonstrate that the inclusion of histidine residues into a multivalent receptor-targeted 




All oligonucleotide (ON) synthesis reagents were purchased from Glen Research (Sterling, 
VA). All maleimide-terminated peptides were purchased as custom order products from 
AnaSpec (Fremont, CA) or Bachem (Torrance, CA). The peptides were characterized by 
HPLC and mass spectrometry by the manufacturer. The peptides used in the conjugation 
reactions are depicted in Table S1 of the Supporting Information.
Numbering of Compounds
The oligonucleotides and conjugates associated with the bolded numerals below are shown 
in Scheme 1 and in Table S2 of the Supporting Information.
Synthesis of Monovalent Bombesin-His6 Conjugated 623 Oliconucleotide (BBN-His6-623-
T, 3)
The 623 oligonucleotide with a 3′ TAMRA fluorophore but without any 5′ conjugation (1, 
623-T) as well as the monomeric bombesin conjugate (2, BBN-623-T) have been previously 
described.22 To prepare 3 a previously described20 thiol oligonucleotide 12 (42.5 nmol) was 
reacted with maleimide-containing bomesin-His6 peptide (118.8 nmol) in a reaction buffer 
(final salt concentration adjusted to 400 mM KCl, 40% aqueous CH3CN, total solution 400 
uL). The reaction mixture was vortexed and allowed to stand for 3 h. The conjugate was 
dialyzed versus milli-Q water (with a Thermo SCIENTIFIC, Slide-A-Lyzer Dialysis 
Cassette, 3500 MWCO). The structure of the conjugate was determined by MALDI-TOF 
mass spectroscopy (AB SCIEX Voyager DE-PRO). The other monovalent conjugates (4, 5, 
6) were also synthesized using the same procedure.
Synthesis of TAMRA-623-TRI-C6-S-S-C6-OH (13)
The branched oligonucleotide 13 was synthesized with an Applied Biosystems 3400 DNA 
synthesizer using DMT-OFF mode. 3′-TAMRA CPG (1000 Ǻ, 1 μmol scale) was used. 
Tris-2,2,2-[3-(4, 4′ dimethoxytrityloxy) propyloxymethyl]-methyleneoxypropyl-[(2-
cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (termed Long trebler phosphoramidite) 
was used to prepare a three-branched ON. Thereafter, 1-O-dimethoxy-trityl-hexyl-disulfide, 
1′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (termed 5′-thiolmodifier C6 S–S 
phosphoramidite) was used to introduce a thiol linker to the 5′-terminal. The coupling times 
for the phosphoramidites of 2′-O-Me RNA, long trebler linker, and modifier C6 S–S linker 
were 300, 900, and 900 s, respectively. 5-(Ethylthio)-1H-tetrazole was used as an activator 
Nakagawa et al. Page 3













(0.25 M solution in acetonitrile), 5% phenoxyacetic anhydride in tetrahydrofuran/pyridine as 
a CAP mix A, and Beaucage reagent was used to introduce the internucleotide 
phosphorothioate backbone. Prior to deprotection, the CPG support was treated with a 10% 
solution of diethylamine in acetonitrile. ON was simultaneously cleaved from the CPG 
support and deprotected using a mixture of tert-butylamine:methanol:water (1:1:2) at 50 °C 
for 16 h. Purification of the oligonucleotide was carried out by reverse-phase HPLC using a 
ZORBAX 300 SB-C18 column (9.4 mm × 250 mm). Finally, the sample was desalted by gel 
filtration with a GE Healthcare illustra NAP-25 column. The structure of the ON (13) was 
determined by ESI mass spectroscopy. A mismatch (MM) version of this ON (14) was also 
synthesized using the same procedure.
Synthesis of TAMRA-623-TRI-C6-SH (15)
The 5′-thiol functionality was generated by treating the disulfide bond of the oligonucleotide 
(13, 40.7 nmol) with 200 uL of 100 mM of aqueous dithiothreitol (DTT) in 0.1 M TEAA 
buffer containing 1% triethylamine. After 30 min reaction, DTT was removed by gel 
filtration with a GE Healthcare illustra NAP-25 column. After the evaporation of water, the 
sample was immediately used for the next conjugation reaction. A mismatch version (16) 
was also synthesized by the same procedure.
Synthesis of Trivalent-Bombesin Conjugated 623 Oligonucleotide (Tri-BBN-623-T, 7)
Trithiol oligonucleotide (15, 67.9 nmol) was reacted with the maleimide-containing 
bombesin peptide (240 nmol) in a reaction buffer (final salt concentration adjusted to 400 
mM KCl, 40% aqueous CH3CN, total solution 400 μL). The reaction mixture stood for 1 h. 
Purification of the oligonucleotide was carried out by reverse-phase HPLC using a 
ZORBAX 300 SB-C18 column (9.4 mm × 250 mm). Finally, the product was dialyzed with 
Slide-A-Lyzer Dialysis Cassette (3500 MWCO, Thermo Scientific). The structure of the ON 
was determined by ESI mass spectroscopy.
Synthesis of Trivalent Bombesin-His6 Conjugated 623 Oligonucleotide (Tri-BBN-His6-623-
T, 8)
Trithiol oligonucleotide (15, 40.7 nmol) was reacted with the maleimide-containing 
Bombesin-His6 peptide (230 nmol) in a reaction buffer (final salt concentration adjusted to 
400 mM KCl, 40% aqueous CH3CN, total volume 600 μL). The reaction mixture stood for 
23 h. Precipitation occurred after the addition of the peptide to the oligonucleotide. After 
reaction, the sample was centrifuged and the supernatant buffer was carefully removed with 
a pipet. The precipitate was washed 4× with milli-Q water. Finally, the product was 
dissolved in formamide. Purification of the conjugate was via reverse phase HPLC as above. 
The structure of the conjugate was determined by ESI mass spectroscopy. The other 
trivalent-peptide conjugates 9, 10, 11 were also synthesized using the same procedure. The 
various conjugates could be solubilized in physiological buffer.
Luciferase Induction Studies—PC3/Luc705 cells were incubated in 24 well plates for 4 
h in serum free medium with oligonucleotide 623 or its various conjugates usually at a 
concentration of 50 nM. Thereafter, serum was added to 1% and the incubation continued 
overnight. In an additional set of experiments, all of the initial incubations were done in the 
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presence of 10% fetal bovine serum. At this point conjugates were removed and the 
incubation continued in medium plus 1% serum to 48 h at which time luciferase and cell 
protein were measured using a Fluostar Omega 96 well plate reader system (BMG, Cary, 
NC). All wells were normalized to protein concentration quantified by a BCA assay (Pierce, 
Rockford, Il). Control conjugates containing an oligonucleotide with 5 mismatches 
(623MM) were also tested.
Time Course of Oligonucleotide Mediated Induction—PC3Luc705 cells were 
seeded in 24 well plates and allowed to adhere overnight. Concentration of oligonucleotide 
stock, 623-TAMRA and Tri-BBN-His-623-TAMRA, was measured at OD260 nm prior to 
treatment. Cells were washed in PBS after which 400 μL OptiMEM media was added to 
each well and the correct volume of oligonucleotide stock was pipetted directly into each 
well to achieve a 50 nM concentration. Cells were incubated at 37 °C for 24, 48, 72, or 96 h 
and harvested for luciferase and protein analysis as above.
Confocal Analysis of Subcellular and Nuclear Colocalization—PC3Luc705 cells 
were seeded in 4 well chamber slides in 10% FBS F12K media and allowed to adhere 
overnight. Cells were washed in PBS and OptiMEM media was added to each well after 
which oligonucleotide, 623-TAMRA, Tri-BBN-623-TAMRA, or Tri-BBN-His-623-Tamra 
was pipetted into the well and cells were incubated at 37 °C for 48 h. Cells were washed 
with PBS and then incubated at 37 °C for 20 min with 4 μM Hoechst 33342 (Life 
Technologies) in 10% FBS F12K media. Hoechst 33342 was washed out and 1% F12K 
media was added to cells. Images were captured on a Olympus FV1000 confocal 
microscope using a Plapon 60×, 1.42 NA oil immersion objective (Olympus). Multiple 
fields of healthy cells were sequentially imaged for TAMRA (549ex/580em) and Hoechst 
33342 (405ex/450em) fluorescence. Colocalization of the two emissions was quantified 
using ImageJ with the JACoP plugin and is represented as Manders colocalization 
coefficient. In some cases, cells were transfected with baculovirus vectors that express 
chimeras of Green Fluorescent Protein and marker proteins for various endomembrane 
compartments (Life Technologies, Organelle Lights).
Uptake Studies
Cell uptake of TAMRA-labeled oligonucleotides and conjugates as a function of time in 
serum free medim or in the presence of 10% fetal bovine serum was measured on the 
Fluostar Omega plate reader system. Values were normalized to cell protein using a BCA 
assay.
RESULTS
The conjugates we prepared are composed of a 2′-O-methyl phosphorothioate splice 
switching antisense oligonucleotide (SSO623) covalently linked to peptides that contain a 
sequence derived from bombesin, several histidine residues, or both. An example is 
illustrated in Figure 1. We examined the biological properties of both monovalent and 
trivalent versions of these conjugates, as well as appropriate mismatched controls. The 
experimental system utilized prostate cancer cells that express the receptor for bombesin and 
Nakagawa et al. Page 5













that are stably transfected with a reporter cassette containing the luciferase coding sequence 
interrupted by an abnormal intron (PC3/Luc705 cells). Effective delivery of an appropriate 
SSO results in correction of splicing and up-regulation of luciferase expression, thus 
providing a convenient positive readout of oligonucleotide delivery to the nucleus.22
The synthesis of the various conjugates is depicted in Scheme 1. The characteristics of the 
various conjugates, including molecular weights obtained by mass spectrometry, are listed in 
Table S2. Synthesis of monovalent conjugates (2–6) closely followed procedures that we 
have previously described,22 while the synthesis, purification, and analysis of trivalent 
bombesin–histidine conjugates (7–11) is described here. Analysis of the various purified 
conjugates is provided in Figure S1 of the Supporting Information. All of the conjugates 
used in this study were able to migrate in nondenaturing 20% polyacrylamide gels, 
indicating that they exist as molecular species and not as highly aggregated material.
Several of the conjugates were evaluated for their ability to achieve correction of splicing 
and thus luciferase induction in the PC3/Luc705 cell system. In these experiments the cells 
were simply incubated with the various oligonucleotides in the absence of any transfection 
agent. As seen in Figure 2, at a concentration of 50 nM oligonucleotide, the trimeric 
conjugate Tri-BBN-His-623 (8), with bombesin and six histidine residues per peptide, was 
substantially more effective than monovalent BBN-623 (2) or than trivalent conjugates that 
containing only bombesin peptide (7) or only the six histidine residues (9). Conjugates with 
a mismatched version of the 623 sequence (10, 11) were completely ineffective. The 
inclusion of histidine residues in a monovalent bombesin conjugate did not improve the 
effect over bombesin alone; thus, multivalency is important (Figure S2). Experiments in the 
presence of 10% serum showed a slight decline in effectiveness of the conjugates but the 
overall pattern was maintained (Figure S3). These differences in luciferase induction likely 
indicate differences in delivery effectiveness, since direct transfection of the various 
conjugates into cells via electroporation revealed only modest differences between the 
compounds (Figure S4) that did not parallel the differences seen in the incubation studies in 
intact cells.
Dose–effect and time–effect relationships for the conjugates are shown in Figure 3A,B. 
These studies demonstrated that the Tri-BBN-His-623 conjugate had a stronger effect than 
several other oligonucleotides and that the onset of the effect was more rapid. We also 
examined trimeric conjugates with fewer than six histidines per peptide (see Table S2), but 
these were significantly less effective (not shown).
We examined the uptake and subcellular localization of the TAMRA labeled conjugates 
using fluorescence detection and confocal microscopy. As seen in Figure S5A, the Tri-BBN-
His-623 conjugate was taken up to a greater degree than Tri-BBN-623 or 623 itself. This 
pattern was also seen in the presence of 10% serum (Figure S5B). Confocal images in live 
cells showed that most of the accumulated Tri-BBN-His-623 was in cytoplasmic vesicles 
including substantial colocalization with the late endosomal marker Rab7, similar to the 
localization 623 itself (Figure 4A,B); this is comparable to the typical subcellular 
distribution of SSOs or antisense oligonucleotides.28 However, colocalization studies using 
the nuclear marker dye Hoechst 33342 revealed a significant increase in nuclear localization 
Nakagawa et al. Page 6













for Tri-BBN-His-623 as compared to the other oligonucleotides (Figure 5A,B). Use of the 
Manders coefficient to evaluate colocalization, as done here, is essentially independent of 
the total fluorescence signal and thus gives a reliable estimate.29 Since phosphorothioate 
oligonucleotides that enter the cytosol rapidly relocalize to the nucleus, this suggests that the 
conjugate is escaping from endosomes and reaching the nucleus to a greater degree than the 
other oligonucleotides tested.
DISCUSSION
We find that inclusion of multiple histidine residues in a targeted oligonucleotide conjugate 
provides a significant increase in pharmacological effectiveness. Several factors may 
contribute to this phenomenon. First, the Tri-BBN-His-623 conjugate is taken up to a greater 
degree than other conjugates. However, it is unlikely that increased cell uptake accounts for 
all of the increased effectiveness. As we have reported previously, intracellular processing 
as well as cell uptake contributes to pharmacological effects.20,22 For example, the Tri-
BBN-623 conjugate is no more effective than the monovalent BBN-623 conjugate even 
though the trivalent form is taken up to a greater extent. The inclusion of multiple histidine 
residues in Tri-BBN-His-623 was designed to provide an endosome escape effect. Our 
studies on nuclear localization using the Hoechst dye marker suggests that this is indeed 
taking place to some degree. However, the presence of histidine residues alone does not 
provide any substantial enhancement over the unconjugated SSO. Thus, the bombesin 
targeting function also clearly plays a role.
The increase in pharmacological effect demonstrated by the current conjugates is modest 
and may not be of therapeutic significance. However, this study demonstrates that it is 
possible to enhance the effectiveness of molecular scale oligonucleotide conjugates by 
rational design, addressing both uptake and endosome escape issues simultaneously. A 
variety of approaches could be followed to pursue increased effectiveness. These might 
include use of longer histidine sequences, incorporating more than one active 
oligonucleotide in the conjugate, or increasing the valency of the conjugates. Thus, it seems 
likely that future studies will evolve novel conjugates with substantially greater 
effectiveness.
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Bombesin–histidine–oligonucleotide conjugate. This depicts one of the multivalent 
conjugates produced. Three peptides containing the bombesin targeting ligand as well as six 
histidines are conjugated to a single 2′-O-methyl phosphorothioate splice switching 
oligonucleotide (oligo 623) via a trimeric linker. The conjugate is also labeled with a 
TAMRA fluorophore at the 3′ position of the oligonucleotide.
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Biological effects of the oligonucleotide conjugates. The conjugates were tested for their 
ability to correct splicing and thus induce luciferase expression in the PC3/Luc705 cell 
system. Results are expressed as relative luminescence units (RLUs) per milligram cell 
protein. Means and standard errors are shown. N = 3–5. The concentration was 50 nM and 
the incubation period 48 h.
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(A) Dose–response. Using similar conditions as in Figure 2, several of the conjugates were 
tested at various concentrations ranging from 25 to 400 nM. Incubation period 48 h. (B) 
Time–response. Using similar conditions, the ability of 623 and Tri-BBN-His-623 to induce 
luciferase was tested as a function of incubation time. Concentration 50 nM. Means and 
standard errors shown. N = 3.
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Subcellular distribution. Cells were transfected with a baculovirus expression vector for a 
Rab7-GFP chimera and subsequently incubated overnight with 200 nM of (A) 623-TAMRA 
or (B) Tri-BBN-His-623-TAMRA. In each panel the upper left is GFP fluorescence, upper 
right phase contrast, lower left TAMRA fluorescence, lower right overlap image.
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Nuclear localization. The subcellular distribution of conjugates in living cells was examined 
using confocal microscopy. (A) Cell images: (i) Tri-BBN-623-TAMRA, (ii) Tri-BBN-
His-623-TAMRA. Upper left panel in each case is Hoechst 33342 fluorescence, upper right 
is TAMRA fluorescence, lower left is the overlap image, lower right phase contrast. (B) 
Quantitation of nuclear localization. The degree of overlap between the TAMRA labeled 
oligonucleotides and the nuclear dye Hoechst 33342 was quantitated by calculation of the 
Manders coefficient. Means and standard errors are shown. N = 13–15.
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